<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329743</url>
  </required_header>
  <id_info>
    <org_study_id>ATR-45-1401</org_study_id>
    <nct_id>NCT02329743</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery</brief_title>
  <official_title>A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.T. Resolve SARL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A.T. Resolve SARL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy and safety of 2 concentrations
      of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of
      ocular inflammation and pain in subjects undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with clearing of anterior inflammation</measure>
    <time_frame>Day 8</time_frame>
    <description>score of zero for the Standardization of Uveitis Nomenclature scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reporting no ocular pain</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Inflammation</condition>
  <condition>Pain</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>RX-10045 0.05% nanomicellar solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RX-10045 0.1% nanomicellar solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10045</intervention_name>
    <description>topical therapy</description>
    <arm_group_label>RX-10045 0.05% nanomicellar solution</arm_group_label>
    <arm_group_label>RX-10045 0.1% nanomicellar solution</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral cataract surgery (phacoemulsification or extracapsular extraction) with
             posterior chamber intraocular lens implantation in the capsular bag.

        Exclusion Criteria:

          -  Any additional surgical procedures at the time of the cataract surgery

          -  Refractive surgery in the study eye within the past 2 years

          -  History or presence of noninfectious inflammatory ocular disease (e.g., episcleritis,
             scleritis, uveitis) in either eye

          -  Intraocular pressure of &gt; 21 mm Hg in either eye

          -  Proliferative or severe nonproliferative diabetic retinopathy in either eye

          -  Neovascular/wet age-related macular degeneration in either eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Sablinski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Auven Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auven Therapeutics</name>
      <address>
        <city>Murray Hill</city>
        <state>New Jersey</state>
        <zip>07974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

